Dabigatran in the ischemic patient undergoing atrial fibrillation ablation

Dabigatran in the ischemic patient undergoing atrial fibrillation ablation

Trans-catheter ablation of atrial fibrillation (AF) is a common treatment for symptomatic AF. Among the major complications of AF ablation are stroke, transient ischemic attacks and peri-procedural cardiac tamponade. Various clinical trials have shown that uninterrupted treatment with vitamin K anta...

Full description

Bibliographic Details
Main Author:	Roberto Spoladore
Format:	Article
Language:	English
Published:	AboutScience Srl 2018-10-01
Series:	AboutOpen
Subjects:	Atrial fibrillation Dabigatran Transcatheter ablation Transient ischemic attack
Online Access:	https://journals.aboutscience.eu/index.php/aboutopen/article/view/137

Similar Items

Non-stop dabigatran
by: Gianluca Manzo
Published: (2018-10-01)

Atrial fibrillation ablation
by: Giuseppe Sgarito
Published: (2018-09-01)

HOW TO USE DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION
by: S. V. Moiseev
Published: (2015-12-01)

Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation
by: Josef Finsterer, et al.
Published: (2012-02-01)

Nationwide survey of catheter ablation for atrial fibrillation: The Japanese catheter ablation registry of atrial fibrillation (J-CARAF)–A report on periprocedural oral anticoagulants
by: Yuji Murakawa, MD, et al.
Published: (2015-02-01)

Comparison of Clinical and Biochemical Parameters in Atrial Fibrillation Patients Using Dabigatran and Rivoraxaban and Their Relationship with Complications
by: İrfan Aydın, et al.
Published: (2020-03-01)

Low Incidence of Atrial Fibrillation in Patients with Transient Ischemic Attack
by: Kenneth Bruun Pedersen, et al.
Published: (2016-11-01)

Uninterrupted Dabigatran Administration Provides Greater Inhibition against Intracardiac Activation of Hemostasis as Compared to Vitamin K Antagonists during Cryoballoon Catheter Ablation of Atrial Fibrillation
by: Zsuzsa Bagoly, et al.
Published: (2020-09-01)

Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE‐CIRCUIT trial
by: Yukihiko Yoshida, et al.
Published: (2018-04-01)

Dabigatran Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation: An Evidence Based Case Report
by: Alvin Nursalim, et al.
Published: (2013-06-01)

Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation
by: N. A. Novikova, et al.
Published: (2016-11-01)

Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland
by: Mark Pletscher, et al.
Published: (2012-12-01)

Newly Diagnosed Atrial Fibrillation After Transient Ischemic Attack Versus Minor Ischemic Stroke in the POINT Trial
by: Hooman Kamel, et al.
Published: (2021-03-01)

Dabigatran etexilate for nonvalvular atrial fibrillation in real practice and promises for its use to prevent stroke
by: A.V. Fonyakin
Published: (2014-06-01)

Dabigatran etexilate in patients with nonvalvular atrial fibrillation: benefits of application in certain clinical situations
by: E. I. Baranova, et al.
Published: (2019-11-01)

Dabigatran and rivaroxaban in the patients with atrial fibrillation and venous thrombembolism: our first clinical experience
by: Alenka Mavri, et al.
Published: (2015-01-01)

Prior Anticoagulation and Short‐ or Long‐Term Clinical Outcomes in Ischemic Stroke or Transient Ischemic Attack Patients With Nonvalvular Atrial Fibrillation
by: Keisuke Tokunaga, et al.
Published: (2019-02-01)

Atrial fibrillation in cancer patients who develop stroke
by: Alia Khamis, et al.
Published: (2022-05-01)

Comparison of benefit between dabigatran and warfarin among patients with atrial fibrillation: A systematic review
by: Amal K Sulieman
Published: (2016-01-01)

Associations of Warfarin Use with Risks of Ischemic Cerebrovascular Events and Major Bleeding in Patients with Hyperthyroidism-Related Atrial Fibrillation
by: Sian-De Liu, et al.
Published: (2022-10-01)

Efficacy and safety of novel anticoagulant dabigatran in clinical practice for Japanese patients with non-valvular atrial fibrillation
by: Koji Miyamoto, et al.
Published: (2014-02-01)

Current approaches to periprocedural anticoagulation treatment in patients undergoing atrial fibrillation ablation
by: N. Z. Gasymova, et al.
Published: (2019-05-01)

Clinical Characteristics of Transient Ischemic Attack Patients with Atrial Fibrillation: Analyses of a Multicenter Retrospective Study
by: Yuka Hama, et al.
Published: (2015-07-01)

Dabigatran in the prevention of stroke in nonvalvular atrial fibrillation: Complex clinical situations and real clinical practice
by: O N Tkacheva, et al.
Published: (2014-04-01)

Possibility of using dabigatran in patients with atrial fibrillation and acute coronary syndrome and PCI
by: A. D. Erlich
Published: (2019-04-01)

Successful use of idarucizumab for the management of intracranial hemorrhage in an elderly woman receiving dabigatran for stroke prevention in atrial fibrillation: A case report
by: Manoj Mashru, et al.
Published: (2018-10-01)

Left Atrial Strain Helps Identifying the Cardioembolic Risk in Transient Ischemic Attacks Patients with Silent Paroxysmal Atrial Fibrillation
by: Arnăutu SF, et al.
Published: (2022-03-01)

DABIGATRAN ETEXILATE FOR PREVENTION OF CARDIOEMBOLIC COMPLICATIONS IN NONVALVULAR ATRIAL FIBRILLATION: HOW TO DO THE INTERVENTION MORE EFFECTIVE AND SAFER
by: I. S. Yavelov
Published: (2016-01-01)

PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION
by: E. D. Kosmacheva, et al.
Published: (2015-09-01)

Reliability and safety of long-term dabigatran use in patients with atrial fibrillation
by: E. V. Serdechnaya, et al.
Published: (2013-04-01)

Effectiveness and safety of dabigatran versus warfarin in “real-world” Japanese patients with atrial fibrillation: A single-center observational study
by: Miyoko Naganuma, PhD, et al.
Published: (2017-04-01)

Post-marketing surveillance on the long-term use of dabigatran in Japanese patients with nonvalvular atrial fibrillation: Preliminary report of the J-dabigatran surveillance
by: Hiroshi Inoue, et al.
Published: (2016-04-01)

Prevalence and Factors Associated with Atrial Fibrillation in Patients with Transient Ischemic Attack or Ischemic Stroke in Northern Vietnam
by: Phan Dinh Phong, et al.
Published: (2023-08-01)

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
by: Faye L. Norby, et al.
Published: (2017-09-01)

First report of dabigatran reversal in iatrogenic pericardial tamponade during catheter ablation of atrial fibrillation
by: Jared D. Miller, MD, et al.
Published: (2017-12-01)

The fate of patients after failed epicardial ablation of atrial fibrillation
by: Giuseppe Nasso, et al.
Published: (2021-09-01)

The preoperative management of dabigatran and its specific antidote idarucizumab in patients with nonvalvular atrial fibrillation: Case reports
by: Tomić Milan
Published: (2020-01-01)

Population pharmacokinetic analysis for dabigatran etexilate in Chinese patients with non-valvular atrial fibrillation
by: Ya-ou Liu, et al.
Published: (2022-10-01)

Observational study of the effects of dabigatran on gastrointestinal symptoms in patients with non-valvular atrial fibrillation
by: Takeshi Yamashita, FJCC, MD, PhD, et al.
Published: (2014-12-01)

Ischemic Stroke and Transient Ischemic Attack Risk Following Vitamin K Antagonist Cessation in Newly Diagnosed Atrial Fibrillation: A Cohort Study
by: Carlos Martinez, et al.
Published: (2020-01-01)